Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Berzofsky Website

Jay A. Berzofsky, M.D., Ph.D.

Selected Publications

1)  Takahashi H, Cohen J, Hosmalin A, Cease KB, Houghten R, Cornette JL, DeLisi C, Moss B, Germain RN, Berzofsky JA.
An immunodominant epitope of the human immunodeficiency virus envelope glycoprotein gp160 recognized by class I major histocompatibility complex molecule-restricted murine cytotoxic T lymphocytes.
Proc. Natl. Acad. Sci. U.S.A. 85: 3105-9, 1988.
[Journal]
2)  Alexander-Miller MA, Leggatt GR, Berzofsky JA.
Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy.
Proc Natl Acad Sci U S A. 93: 4102-7, 1996.
[Journal]
3)  Terabe M, Matsui S, Noben-Trauth N, Chen H, Watson C, Donaldson DD, Carbone DP, Paul WE, Berzofsky JA.
NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway.
Nat Immunol. 1: 515-20, 2000.
[Journal]
4)  Terabe M, Swann J, Ambrosino E, Sinha P, Takaku S, Hayakawa Y, Godfrey DI, Ostrand-Rosenberg S, Smyth MJ, Berzofsky JA.
A nonclassical non-Valpha14Jalpha18 CD1d-restricted (type II) NKT cell is sufficient for down-regulation of tumor immunosurveillance.
J Exp Med. 202: 1627-33, 2005.
[Journal]
5)  Zhu Q, Talton J, Zhang G, Cunningham T, Wang Z, Waters RC, Kirk J, Eppler B, Klinman DM, Sui Y, Gagnon S, Belyakov IM, Mumper RJ, Berzofsky JA.
Large intestine-targeted, nanoparticle-releasing oral vaccine to control genitorectal viral infection.
Nat. Med. 18: 1291-6, 2012.
[Journal]
6)  Chen Z, Ozbun L, Chong N, Wallecha A, Berzofsky JA, Khleif SN.
Episomal expression of a truncated listeriolysin O in LmddA-LLO-E7 vaccine enhances anti-tumor efficacy by preferentially inducing CD4+FoxP3- T cell and CD8+ T cell expansion.
Cancer Immunol Res. [Epub ahead of print], 2014.
[Journal]
7)  Vargas-Inchaustegui DA, Tuero I, Mohanram V, Musich T, Pegu P, Valentin A, Sui Y, Rosati M, Bear J, Venzon DJ, Kulkarni V, Alicea C, Pilkington GR, Liyanage NP, Demberg T, Gordon SN, Wang Y, Hogg AE, Frey B, Patterson LJ, DiPasquale J, Montefiori DC, Sardesai NY, Reed SG, Berzofsky JA, Franchini G, Felber BK, Pavlakis GN, Robert-Guroff M.
Humoral immunity induced by mucosal and/or systemic SIV-specific vaccine platforms suggests novel combinatorial approaches for enhancing responses.
Clin. Immunol. [Epub ahead of print], 2014.
[Journal]
8)  Morris JC, Tan AR, Olencki TE, Shapiro GI, Dezube BJ, Reiss M, Hsu FJ, Berzofsky JA, Lawrence DP.
Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-beta (TGFß) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma.
PLoS ONE. 9: e90353, 2014.
[Journal]
9)  Terabe M, Berzofsky JA.
The immunoregulatory role of type I and type II NKT cells in cancer and other diseases.
Cancer Immunol. Immunother. 63: 199-213, 2014.
[Journal]
10)  Sui Y, Hogg A, Wang Y, Frey B, Yu H, Xia Z, Venzon D, McKinnon K, Smedley J, Gathuka M, Klinman D, Keele BF, Langermann S, Liu L, Franchini G, Berzofsky JA.
Vaccine-induced myeloid cell population dampens protective immunity to SIV.
J. Clin. Invest. 124: 2538-49, 2014.
[Journal]
Click Here to View Expanded Bibliography.

This page was last updated on 6/17/2014.